series-c-plus
Stage
1
Investors
About
HanchorBio develops Fc-Based Designer Biologics (FBDB™) that create ligand traps to block multi-ligand immune interactions; its lead candidate HCB101 is in US Phase 1 clinical trials targeting the SIPRα-CD47 pathway for advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma.
Explore HanchorBio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.